Navigation Links
Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation

Initial Analysis Shows Statistically Significant Changes in Agitation Levels With 10 mg AZ-004

PALO ALTO, Calif., March 26, 2007 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. today announced positive initial results from its Phase IIa clinical trial of AZ-004 (Staccato(R) loxapine) in schizophrenic patients with acute agitation. The 10 mg dose of AZ-004 met the primary endpoint of the clinical trial, which was a statistically-significant reduction in the measure of agitation from baseline to the 2-hour post-dose time point, compared to placebo. Alexza also announced today positive top-line results from its Phase IIb clinical trial of AZ-001 (Staccato prochlorperazine) in patients with migraine headache, where AZ-001 met the primary endpoint of the Phase IIb clinical trial.

"AZ-004 is a product candidate that we believe could fill an important unmet need in the acute treatment of agitation in schizophrenic patients," said Thomas B. King, President and CEO of Alexza. "AZ-004 combines drug delivery speed comparable to that of an intravenous injection, but with the simplicity, convenience and ease of administration of a simple, one-breath inhalation."

"Antipsychotic drugs used to treat acute agitation are typically administered by intramuscular injection, usually in a clinic or in an emergency department," said James V. Cassella, PhD, Senior Vice President, Research and Development of Alexza. "The ability to provide a proven drug mechanism of action, coupled with rapid pharmacokinetics and patient self-administration, makes Staccato loxapine a potentially important new drug candidate for treating agitation in schizophrenic patients."

Clinical Trial Design

The Phase IIa clinical trial was designed as a multi-center, randomized, double-blind, placebo-controlled study of 120 patients in an in-patient clinical setting. In the trial, two doses of AZ-004 (Staccato loxapine in 5 and 10
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-004 (Staccato Loxapine) Clinical Data at the Annual NCDEU Meeting
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:10/1/2014)... SAN MARCOS, Texas , Oct. 1, 2014 ... that it is scaling volume production of photoactive ... solar power technologies . While offering numerous advantages ... difficulty of producing large quantities of quantum dots ... has until now kept them from commercial utilization ...
(Date:10/1/2014)... -- SI-BONE, Inc., a medical device company that pioneered the use ... surgical (MIS) device indicated for fusion for certain disorders of ... European operations with the formation of a GmbH and the ... Germany.  Mr. Schaber will join former Kyphon colleague Andrea ... , Middle East and Asia Operations ...
(Date:10/1/2014)... R.I. , Oct. 1, 2014  CVS Health ... Month for their role in changing the way health ... improve quality in the Company,s retail pharmacies, mail service ... month, we changed our company name to CVS Health ... expertise in driving the innovations needed to shape the ...
Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3
... Percent of Nucleoside-Naive Chronic Hepatitis B e-Antigen,(HBeAg)-Negative ... of Re-Treatment, PRINCETON, N.J., April 13, 2007 ... from a cohort of,nucleoside-naive HBeAg-negative chronic hepatitis ... patients who,experienced recurrent levels of hepatitis B ...
... Ascenta Therapeutics,Inc. announced today that its small molecule ... oral,presentations and several poster presentations at next week's ... Research,(AACR), to be held in Los Angeles, California ... selected for presentation at the,"High Impact Late-Breaking Research ...
Cached Medicine Technology:Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment 2Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment 3Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment 4Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment 5Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 2Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 3Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 4Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 5Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 6
(Date:10/2/2014)... October 02, 2014 There has been ... new demand has resulted in an increase in the ... of different services at very affordable prices. A leading ... many professional SEO hosting companies and announced that InMotion ... who want to buy hosting products. , InMotion ( ...
(Date:10/2/2014)... PA (PRWEB) October 02, 2014 ... of the 2014 BIG Awards for Business program. ... and organizations with a proprietary judging process scored ... around the globe. , “The winners this year ... Russ Fordyce, Managing Director of the Business Intelligence ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, ... a neurotic personality style and prolonged stress may have ... suggests. Tracking 800 women over nearly four decades, ... jealous and moody -- which they defined as neurotic ... of developing Alzheimer,s compared to women scoring lowest in ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 ... raise your risk for high blood pressure, a new study ... lived within 109 yards of a busy road had a ... women living at least half a mile away, researchers report. ... of our physical environment on our health and well-being," said ...
(Date:10/2/2014)... Dennis Thompson HealthDay ... Forty-two states and the District of Columbia now have a ... respiratory illness that has been infecting children since the ... with the virus have died in recent weeks, but it,s ... played in those deaths, officials said. Health officials are ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3
... A new study that is to appear in the May ... American Cancer Society says that weight training// improves the quality ... breast cancer. A bi-weekly exercise regimen for six months improves ... ,In the initial days after therapy for breast cancer, ...
... need to perform more physical activities or exercise to keep themselves ... people age, there is a decline in the exercise or work ... led by Wayne C. Levy at the University of Washington in ... aging cardiovascular system being less able to send oxygen to working ...
... danced to the taste buds of many a watering mouth. Yet, ... somber//. Cast away from star hotels and foreign trips, to land ... say the least! ,Taking a trip down memory lane, ... own sons of the soil-amongst people in small towns and villages, ...
... Defence Minister Pranab Mukherjee has urged the military doctors to ... services, in the rapidly changing global scenario in order to ... are the most potent form of delivering healthcare both to ... disasters, the minister said while opening the 16th Asia-Pacific Military ...
... used gene technology to breed animals that produce fats. The ... key gene inserted in them. // ,The result was ... produce compounds useful for the heart. ,According to researcher Dr ... could use these animals as a model to see what happens ...
... planned to open a laboratory to test for the avian ... laboratory may come up in the Keoladeo Ghana bird sanctuary ... Ghana was chosen because thousands of birds from various countries ... in the region. ,The Bharatpur sanctuary is ...
Cached Medicine News:Health News:Pranab Mukherjee Urged Military Doctors To Remain On The Cutting Edge 2
Single channel module for Finnpipette Biocontrol - Universal handle sold separately...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
An automatic system for determining erythrocyte sedimentation rate (ESR) in EDTA tube and using cell counter racks....
MiniVes has been specifically designed for the doctors office and near patient testing and it uses normally freshly collected blood that shall be mixed manually by 15 complete inversion of the tube a...
Medicine Products: